Allan Coates, DO
Gastroenterology · Wyoming, MINPI 1972510378
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 33.9% of the total. That places this record below the midpoint for gastroenterology clinicians in MI, where the typical reported total is $1,620.
Across 131 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$672
- Takeda Pharmaceuticals U.S.A., Inc.$225
- Pfizer$154
- Merz North America, Inc.$127
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$113
- Ipsen Biopharmaceuticals, Inc$96
- plus $594 from 17 others
Across 2,444 payments — averaging $2457.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.4M
- Intercept Pharmaceuticals, Inc.$983K
- AbbVie$829K
- Bristol Myers Squibb$418K
- Eli Lilly$356K
- Teva Pharmaceuticals USA, Inc.$311K
- plus $1.7M from 24 others
What the payments were for
- Food & beverage$1,94798%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $672 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $225 |
| Pfizer | 19 | $154 |
| Merz North America, Inc. | 2 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $113 |
| Ipsen Biopharmaceuticals, Inc | 5 | $96 |
| Bristol Myers Squibb | 5 | $94 |
| Johnson & Johnson | 6 | $76 |
| Madrigal Pharmaceuticals | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Gilead | 3 | $41 |
| Shionogi Inc | 2 | $34 |
| Merck | 2 | $34 |
| Organogenesis Inc. | 1 | $30 |
| Axonics, Inc. | 1 | $29 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Capsovision, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Braintree Laboratories, Inc. | 1 | $12 |
How this compares
$1,982 in reported general payments places this provider in the 50th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 18 | $502,543 |
| Humira(Cf) PenAdalimumab | 45 | $334,150 |
| CreonLipase/Protease/Amylase | 25 | $37,986 |
| LinzessLinaclotide | 30 | $28,358 |
| Dexlansoprazole DrDexlansoprazole | 33 | $8,626 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 52 | $8,313 |
| Ursodiol | 30 | $7,776 |
| CholestyramineCholestyramine (With Sugar) | 48 | $4,735 |
| Balsalazide Disodium | 25 | $4,640 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 191 | $3,373 |
| Omeprazole | 203 | $3,046 |
| Pantoprazole Sodium | 128 | $2,960 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 137 | $2,404 |
| Azathioprine | 29 | $1,791 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 13 | $1,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $76 | $502,54318 claims |
| AbbVieCreon, Linzess | $672 | $66,34455 claims |
| Braintree Laboratories, Inc.Sutab | $12 | $8,31352 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $113 | $1,71813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 497 gastroenterology providers in Michigan.
Other gastroenterology in Wyoming
- Kimberly BrownDetroit$733K
- Dilip MoonkaDetroit$611K
- Philip SchoenfeldAnn Arbor$539K
- Michelle Muza-MoonsAnn Arbor$481K
- Partha NandiTroy$377K
- Bradford WhitmerSaint Clair Shores$206K
- Mohammed BarawiSt Clair Shores$193K
- Stuart GordonDetroit$178K
- Mohamad AlsibaeRoyal Oak$127K
- Allison SchulmanAnn Arbor$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.